MX2021011407A - Proteinas de dominio ccn recombinantes y proteinas de fusion. - Google Patents

Proteinas de dominio ccn recombinantes y proteinas de fusion.

Info

Publication number
MX2021011407A
MX2021011407A MX2021011407A MX2021011407A MX2021011407A MX 2021011407 A MX2021011407 A MX 2021011407A MX 2021011407 A MX2021011407 A MX 2021011407A MX 2021011407 A MX2021011407 A MX 2021011407A MX 2021011407 A MX2021011407 A MX 2021011407A
Authority
MX
Mexico
Prior art keywords
proteins
recombinant
fusion
ccn
fusion proteins
Prior art date
Application number
MX2021011407A
Other languages
English (en)
Inventor
Håvard Attramadal
KAASBØLL Ole Jørgen
Original Assignee
Univ Oslo Hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oslo Hf filed Critical Univ Oslo Hf
Publication of MX2021011407A publication Critical patent/MX2021011407A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a proteínas recombinantes que tienen una secuencia de aminoácidos correspondiente o relacionada con el dominio de homología de repetición de trombospondina tipo 1 de un miembro de las proteínas de la familia CCN y el uso de las mismas. Además, la presente invención se refiere a proteínas de fusión que comprenden una secuencia de aminoácidos correspondiente o relacionada con el dominio de homología de repetición de trombospondina tipo 1 de un miembro de la familia de proteínas CCN combinado con un compañero de fusión y opcionalmente una región conectora. Además, en el presente documento se divulgan nuevos fragmentos Fc resistentes a proteasas.
MX2021011407A 2019-03-20 2020-03-20 Proteinas de dominio ccn recombinantes y proteinas de fusion. MX2021011407A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19163970.7A EP3711772A1 (en) 2019-03-20 2019-03-20 Recombinant proteins and fusion proteins
PCT/EP2020/057773 WO2020188081A1 (en) 2019-03-20 2020-03-20 Recombinant ccn domain proteins and fusion proteins

Publications (1)

Publication Number Publication Date
MX2021011407A true MX2021011407A (es) 2022-01-24

Family

ID=66102364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011407A MX2021011407A (es) 2019-03-20 2020-03-20 Proteinas de dominio ccn recombinantes y proteinas de fusion.

Country Status (12)

Country Link
US (1) US20220144903A1 (es)
EP (2) EP3711772A1 (es)
JP (1) JP2022525661A (es)
KR (1) KR20210142681A (es)
CN (1) CN113747912A (es)
AU (1) AU2020243073A1 (es)
BR (1) BR112021017147A2 (es)
CA (1) CA3133740A1 (es)
IL (1) IL285930A (es)
MX (1) MX2021011407A (es)
SG (1) SG11202109738QA (es)
WO (1) WO2020188081A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047556A2 (en) * 1998-03-19 1999-09-23 Trustees Of Tufts College Novel heparin-induced ccn-like molecules and uses therefor
FR2858234B1 (fr) * 2003-08-01 2007-09-14 Centre Nat Rech Scient Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers
ES2395260T3 (es) * 2005-01-10 2013-02-11 Rosalind Franklin University Of Medicine And Science Proteína CCN3 para su utilización en el tratamiento y el diagnóstico de enfermedades renales
JP5127043B2 (ja) * 2005-01-24 2013-01-23 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ホスファチジルセリンに結合するｆｃ融合構築物およびそれらの治療用途
WO2007033215A2 (en) * 2005-09-12 2007-03-22 The Johns Hopkins University Compositions having antiangiogenic activity and uses thereof
JP2009067678A (ja) * 2005-12-07 2009-04-02 Nihon Nosan Kogyo Kk 結合組織増殖因子に対する抗体又はそれを含む組成物
US20080207489A1 (en) 2007-02-21 2008-08-28 John Castellot Use of CCN5 for treatment of smooth muscle proliferation disorders
EP3061817B1 (en) * 2009-04-30 2018-12-12 Kao Corporation Alkaline protease variants
JP5820378B2 (ja) * 2009-09-09 2015-11-24 ファーマイン コーポレーションＰｈａｒｍａｉｎ Ｃｏｒｐｏｒａｔｉｏｎ 治療剤の送達のための陰イオンコア組成物およびその製造ならびに使用方法
KR101187814B1 (ko) 2010-03-22 2012-10-08 광주과학기술원 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법
US9114112B2 (en) * 2010-04-02 2015-08-25 Rosalind Franklin University Of Medicine And Science CCN3 and CCN3 peptides and analogs thereof for therapeutic uses
CN102947326B (zh) * 2010-04-02 2016-02-10 罗莎琳德富兰克林大学医学与科学院 用于治疗用途的ccn3肽以及其类似物
DK2654780T3 (en) 2010-12-23 2017-04-10 Janssen Biotech Inc ACTIVE PROTEASE-RESISTANT ANTIBODY-FC MUTANTS
GB201316592D0 (en) 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
CN105396136B (zh) * 2015-11-23 2018-10-30 上海交通大学医学院附属第九人民医院 CCN1（Cyr61）在治疗皮肤损伤及皮肤萎缩相关疾病中的应用
CN116239693A (zh) 2016-03-14 2023-06-09 奥斯陆大学 具有改变的FcRn结合的工程化免疫球蛋白
US20180127478A1 (en) 2016-09-16 2018-05-10 Wei-Chiang Shen SINGLE CHAIN Fc-DIMER-HUMAN GROWTH HORMONE FUSION PROTEIN FOR IMPROVED DRUG DELIVERY
KR20180099537A (ko) * 2017-02-28 2018-09-05 주식회사 파이안바이오테크놀로지 근섬유모세포의 병리적 활성이 초래하는 섬유증식성 질병 치료제

Also Published As

Publication number Publication date
SG11202109738QA (en) 2021-10-28
CN113747912A (zh) 2021-12-03
WO2020188081A1 (en) 2020-09-24
JP2022525661A (ja) 2022-05-18
EP3711772A1 (en) 2020-09-23
IL285930A (en) 2021-10-31
US20220144903A1 (en) 2022-05-12
CA3133740A1 (en) 2020-09-24
EP3941507A1 (en) 2022-01-26
BR112021017147A2 (pt) 2021-11-09
AU2020243073A1 (en) 2021-11-11
KR20210142681A (ko) 2021-11-25

Similar Documents

Publication Publication Date Title
CL2019001000A1 (es) Proteínas de fusión fc heterodiméricas il15/il15ralfa
UA124343C2 (uk) Капсиди аденоасоційованого вірусу і спосіб його використання
ES2676499T3 (es) Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
EA201691111A1 (ru) Химерные белки фактора viii и их применение
NZ602634A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
MA34802B1 (fr) Nouvel antigène
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
TW200722436A (en) A peptide-immunoglobulin-conjugate
MX2021008131A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
MX2021002295A (es) Variantes de proteinas recombinantes.
MX2021013743A (es) Subunidad s1 modificada de la proteina de espicula de coronavirus.
MX2023001595A (es) Proteinas de fusion que comprenden proteinas de leche y composiciones de las mismas.
EA201892554A1 (ru) Мутант cd200 и его применения
PL415888A1 (pl) Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie
ATE453663T1 (de) Zusammensetzungen von für pathogene stämme spezifischen polypeptiden und deren verwendung als impfstoffe und in der immuntherapie
MX2020013158A (es) Proteina cas9 modificada y uso de la misma.
MX2021011407A (es) Proteinas de dominio ccn recombinantes y proteinas de fusion.
MX2022007881A (es) Proteina f mutante del virus sincitial respiratorio (rsv) y usos de la misma.
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
SE0302103D0 (sv) Xylanases with enhanced thermophilicity and alkalophilicity
PH12021551055A1 (en) Klk5 inhibitory peptide
EA202092963A1 (ru) Новый белок с противовоспалительными свойствами
NZ751995A (en) Modified factor h binding protein